Skip to main content
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- Trade Name: Rhopressa (Aerie)
- Indications: Reduction of elevated intraocular pressure in open angle glaucoma or ocular hypertension
- Class: Rho kinase inhibitor
- Half-life: N/A
- FDA Approval Date: 12/18/2017
- Clinically important, potentially hazardous interactions with:
None known - Pregnancy: No available data to inform drug-associated risk
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
